Shares of Apellis Pharmaceuticals, Inc. (APLS) are falling more than 21 percent Thursday morning after the company said it expects the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) to give a negative opinion on its marketing authorization application for Pegcetacoplan to treat geographic atrophy.
Geographic atrophy, an advanced form of dry age-related macular degeneration (AMD), causes central vision loss.
CHMP is expected to provide its opinion on Pegcetacoplan at its next meeting scheduled between January 22 and 25.
APLS, currently at $49.56, has traded in the range of $19.83 - $94.75 in the last 1 year.
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.